Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

BACKGROUND: Up to now, immunisation regimens that have been assessed for development of HIV vaccines have included purified envelope (Env) protein among the boosting components of the regimen. We postulated that co-administration of Env protein with either a DNA or NYVAC vector during priming would...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet HIV
Auteurs principaux: Pantaleo, Giuseppe, Janes, Holly, Karuna, Shelly, Grant, Shannon, Ouedraogo, G Laissa, Allen, Mary, Tomaras, Georgia D, Frahm, Nicole, Montefiori, David C, Ferrari, Guido, Ding, Song, Lee, Carter, Robb, Merlin L, Esteban, Mariano, Wagner, Ralf, Bart, Pierre-Alexandre, Rettby, Nils, McElrath, M Juliana, Gilbert, Peter B, Kublin, James G, Corey, Lawrence
Format: Artigo
Langue:Inglês
Publié: Elsevier B.V 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156919/
https://ncbi.nlm.nih.gov/pubmed/31601541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(19)30262-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires